NASH: Evaluating Emerging Diagnostic and Treatment Strategies
Source: NASH: Evaluating Emerging Diagnostic and Treatment Strategies

Video Module

In this on-demand Webcast, expert faculty review the latest diagnostic resources, emerging and investigational therapies, and strategies for improving the care of patients with NASH.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients who should undergo assessment for NAFLD/NASH
  • Utilize invasive and noninvasive tools to diagnose NASH and predict patient outcomes
  • Apply current best practices in the management of NASH, including lifestyle changes and pharmacologic therapies
  • Counsel patients on progress of investigational therapies for NASH, including mechanisms of action, safety, and hepatic efficacy outcomes
CCO Video Modules contain video commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.
 

Program Directors

  • Stephen A. Harrison
    MD, COL (Ret.), FAASLD

Faculty

  • Quentin M. Anstee
    BSc, MB BS, PhD, MRCP(UK), FRCP
    Mary E. Rinella
    MD

Credit Information

  • Release Date:
    December 23, 2016
  • Expiration Date:
    December 22, 2017
  • Physicians:
    maximum of 2.0 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

Program Directors

Stephen A. Harrison, MD, COL (Ret.), FAASLD

Visiting Professor of Hepatology
Radcliffe Department of Medicine
University of Oxford
Oxford, United Kingdom

Stephen A. Harrison, MD, COL (Ret.), FAASLD, has disclosed that he has received consulting fees from Bristol-Myers Squibb, the Chronic Liver Disease Foundation, FibroGen, Genfit, Intercept, Medivation, Merck, NGM Biopharmaceuticals, and Pfizer; has received fees for non-CME/CE services from AbbVie, Alexion, Gilead Sciences, and Merck; and funds for research support paid to his institution from Bristol-Myers Squibb, Conatus, Galectin, Galmed, Gilead Sciences, Immuron, Intercept, Madrigal, Merck, NGM Biopharmaceuticals, and Tobira.

 

Faculty

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP


Professor of Experimental Hepatology 
Consultant Hepatologist
Institute of Cellular Medicine
Newcastle University
Newcastle Upon Tyne, United Kingdom

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP, has disclosed that he has received consulting fees paid to his institution from Acuitas Medical, Genfit, Intercept, Inventiva, Janssen, Lilly, NewGene, Pfizer, Raptor Pharmaceuticals, and Tobira and funds for research support paid to his institution from AbbVie and GlaxoSmithKline.

 

Mary E. Rinella, MD


Associate Professor of Medicine
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Mary E. Rinella, MD, has disclosed that she has received consulting fees from Amarin, BioPharma, Echosens, Enanta, Immuron, Intercept, NGM Biopharmaceuticals, and NuSirt.

 

Staff

Zachary Schwartz, MSc, ELS


Managing Editor

Zachary Schwartz, MSc, ELS, has no real or apparent conflicts of interest to report.

 

Megan K. Murphy, PhD


Clinical Editor

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.

 

Monique Carasso, MSN, ANP-C


Staff Faculty
Adult Nurse Practitioner
Division of Medicine, Hepatology
Weill Cornell Medical College
New York, New York

Megan Cartwright, PhD, has no real or apparent conflicts of interest to report.

 

Kiran D. Mir-Hudgeons, PhD


Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no real or apparent conflicts of interest to report.

 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This program is intended for physicians and other healthcare providers involved in the care of patients with NASH.


Goal

The goal of this activity is to improve participants’ confidence and competence in diagnosing and managing patients with NASH, as well as to improve participants’ knowledge of emerging and investigational therapies for the management of NASH.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify patients who should undergo assessment for NAFLD/NASH
  • Utilize invasive and noninvasive tools to diagnose NASH and predict patient outcomes
  • Apply current best practices in the management of NASH, including lifestyle changes and pharmacologic therapies
  • Counsel patients on progress of investigational therapies for NASH, including mechanisms of action, safety, and hepatic efficacy outcomes
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by an educational grant from Intercept Pharmaceuticals, Inc..

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 23, 2016, through December 22, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.